Investor's Business Dailyadded this to Tech NewsBiogen Biogen Earnings Crush Forecasts; But Pay Attention To These Two Elementsinvestors.com - ALLISON GATLIN Biogen stock jumped early Tuesday after the biotech company topped Wall Street's second-quarter estimates and formally unveiled an experimental …
The Motley FoolInvesting Are These 2 Beaten-Down Biotech Stocks Worth Buying?The Motley Fool - George Budwell Acadia Pharmaceuticals and Dynavax Technologies are having a rough week. Biotech stocks that fall hard and fast can sometimes turn out to be …
Investing.com UKadded this to UK NewsCoca-Cola Stocks - Lockheed Martin, Hasbro, Coca-Cola, Starbucks Rise Premarketinvesting.com Starbucks (NASDAQ:SBUX) stock ticked up 0.6% after the beverage chain made a licensing deal with restaurant tech company Brightloom. The deal will …
MarketWatchadded this to BusinessBiogen Biogen's stock jumps after big earnings beat, raised outlookMarketWatch - By Tomi Kilgore Shares of Biogen Inc. BIIB, +0.52% surged 5.0% in premarket trading Tuesday, after the biotechnology company reported second-quarter earnings and …
The Evening Standardadded this to Business | Evening StandardBrexit Market report: Biotech firm Abcam rallies on bid talk as impatient investors eye salestandard.co.uk - Mark Shapland Shares in AIM-listed Abcam shot higher today amid speculation that the biotechnology company could be snapped up by a larger rival. Yesterday its …
Seeking AlphaInvesting Alnylam's Onpattro OK'd in Canada for hATTRSeeking Alpha - Douglas W. House Alnylam Pharmaceuticals (ALNY -0.1%) announces Health Canada approval and the immediate availability of ONPATTRO (patisiran) for the treatment of …
Seeking AlphaInvesting Biotechs' Second-Half BattleSeeking Alpha - Tarun Chandra, CFA The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index (IBB) …
National Reviewadded this to The CornerFlipboardIcon version of the Flipboard logoGenome Editing Slouching toward ‘Brave New World’National Review - Wesley J. Smith Genetic engineering is among the most powerful human technologies ever invented. It holds great hope for everything from medical uses to cleaning up …
The Wall Street Journal.IPOs Valuations Rise for Biotech Companies Going PublicThe Wall Street Journal. - Brian GormleyPublic investors see opportunity for drug startups to be acquired Biotechnology startups are commanding higher prices in their initial public offerings, a sign of investors’ growing faith in small drugmakers.
Investor's Business Dailyadded this to Tech NewsBiogen Biogen Earnings: Here's What Investors Are Hoping To See In Reportinvestors.com - ALLISON GATLIN Investors will key into Biogen earnings Tuesday to better understand the biotech company's ongoing efforts in Alzheimer's treatment, an analyst said …
Seeking AlphaInvesting Amarin: Valuations Are Still Attractive, This Biotech Stock Is Set To FlySeeking Alpha - Value Kicker When building out a diversified portfolio to beat the market (I mean the website is called Seeking Alpha, not Seeking Beta), it is useful to add a …
The Motley FoolInvesting What Happens If Pacific Biosciences Isn't Acquired By Illumina?The Motley Fool - Maxx Chatsko Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors. A nervous energy …
The Wall Street Journal.added this to MarketsInvesting Stocks Surge on China's New Nasdaq-Like MarketThe Wall Street Journal. - Shen HongSHANGHAI—China’s new market for homegrown technology companies opened with a bang, with stocks doubling, tripling or more than quadrupling in value on its first day. The Shanghai Stock Exchange’s Science
Sociology Beneath the Facadethesocietypages.org - Ana Meisel on July 22, 2019 While putting together the most recent project for External Pages, I have had the pleasure to work with artist and designer Anna Tokareva in …
Business Insider Deutschlandadded this to Business InsiderNovartis Novartis CEO Vas Narasimhan interview on M&A and deal strategyBusiness Insider - Emma Court, Matt TurnerWhen Vas Narasimhan started as the new CEO of Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling psoriasis,
Barron'sadded this to Barron'sNovartis Novartis Posts Strong Earnings, but Is Mum on Sales of Its New Gene TherapyBarron's - Josh Nathan-Kazis Shares of Swiss drugmaker Novartis AG (ticker: NVS) were rising on Friday on a strong earnings report, but the company released limited information …
ga titoadded this to MarketHarley Davidson 3 Top Dividend Stocks With Yields Over 4%The Motley Fool - Rich Duprey, George Budwell, and Keith Noonan Check out why above-average dividend payers AT&T, AbbVie, and Harley-Davidson might be good long-term picks. Even with an improving economy, many are …
AxiosMedicare 3. Landmark opioids trial concludesAxios Good morning... Here's a sign of the times: Sotheby's is about to hold its first-ever sneaker auction. The distance between popular culture and high …
Barron'sadded this to Barron'sInvesting How to Invest in Health-Care Stocks Under the Shadow of Medicare for AllBarron's - Josh Nathan-Kazis Before he took over one of the best-performing health-care funds, Ziad Bakri was a medical resident in the emergency room of the Royal London …
FlipboardIcon version of the Flipboard logoInvesting Baxter International Inc Stock Quote: BAX Stock News, Quotes, Analysis |investors.com - Investor's Business Daily 07/11/2019 03:00 AM ET Baxter International (BAX) is expected to report earnings on Jul. 25. The stock is now trading right around the 82.35 ... Baxter International (BAX) …
PPeak Bggradded this to Biotech InvestingInvesting Mirati Is The Biotech To Watch As Second Half Catalyst Rapidly ApproachesSeeking Alpha - Terry Chrisomalis Mirati Therapeutics (MRTX) announced that it had formed a collaboration agreement with Novartis (NVS) to target patients with advanced solid tumors. …
Novartis The Multibillion-Dollar Race for Gene Therapy Manufacturing Is Onyahoo.com - Maxx Chatsko, The Motley Fool Gene therapy, a promising therapeutic approach that corrects disease-causing genetic errors, has spurred an arms race among the world's largest …
St. Louis Post-Dispatchadded this to St. Louis businessSt. Louis, MO Report lists $5 million of recent venture capital investments in St. Louisstltoday.com - David Nicklaus Venture capital deals are booming in the U.S. but in a bit of a lull in the St. Louis area, the latest MoneyTree report says. The report, compiled by …
Entrepreneuradded this to EntrepreneursStartups How 3 Words Helped Change This Man's CareerEntrepreneur - MaRS Discovery DistrictThe founder of this biotech company explains how he was able to change careers and pinpoint his passion. In this video, Entrepreneur Network partner Mars Discovery District speaks with Carlo Perez about
FlipboardIcon version of the Flipboard logoTSX Venture Exchange LexaGene Files Three Additional US Patents Covering Technologyyahoo.com - GlobeNewswire BEVERLY, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that …
Reutersadded this to BusinessNeil Woodford Exclusive: Woodford biotech stakes first off block in asset sale - sourceReuters - By Pamela Barbaglia, Carolyn Cohn and Douglas BusvineLONDON/FRANKFURT (Reuters) - British fund manager Neil Woodford is looking to kick off the sale of his unlisted biotech investments at the end of July, but faces months of negotiations to offload the a
The Telegraphadded this to BusinessNeil Woodford Neil Woodford to start offloading unlisted biotech holdings this monthThe Telegraph - By Harriet RussellEmbattled fund manager Neil Woodford could start offloading holdings in unlisted biotech companies at the end of this month, although it remains unclear how long the sales will take or when investors have
PPeak Bggradded this to Biotech InvestingInvesting Why Inovio Pharmaceuticals Stock Is Plunging TodayThe Motley Fool - George Budwell Shareholders are none too pleased with Inovio's cost-cutting initiative. Here's why. Shares of the clinical-stage vaccine company Inovio …
Seeking AlphaInvesting Clinuvel: Bubbling And Ready To BurstSeeking Alpha - Tien Duy Vo Clinuvel (OTCPK:CLVLY) is a small biotech company which focuses on bringing the first-in-class drug for the treatment of EPP (Erythropoietic …
The Motley FoolGilead Sciences Gilead's Galapagos Deal: What It Means for InvestorsThe Motley Fool - Keith Speights Here's what Gilead's getting with its $5.1 billion Galapagos collaboration. Anyone wondering what the first major move of Gilead Sciences' …
